HUE057301T2 - Bariátriai eljárást követõ hipoglikémia kezelése GLP-1 antagonistákkal - Google Patents

Bariátriai eljárást követõ hipoglikémia kezelése GLP-1 antagonistákkal

Info

Publication number
HUE057301T2
HUE057301T2 HUE16800620A HUE16800620A HUE057301T2 HU E057301 T2 HUE057301 T2 HU E057301T2 HU E16800620 A HUE16800620 A HU E16800620A HU E16800620 A HUE16800620 A HU E16800620A HU E057301 T2 HUE057301 T2 HU E057301T2
Authority
HU
Hungary
Prior art keywords
glp
antagonists
post
treatment
bariatric hypoglycemia
Prior art date
Application number
HUE16800620A
Other languages
English (en)
Inventor
Tracey L Mclaughlin
Colleen M Craig
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of HUE057301T2 publication Critical patent/HUE057301T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
HUE16800620A 2015-05-22 2016-05-23 Bariátriai eljárást követõ hipoglikémia kezelése GLP-1 antagonistákkal HUE057301T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165743P 2015-05-22 2015-05-22
US201562254175P 2015-11-11 2015-11-11
US201662329850P 2016-04-29 2016-04-29

Publications (1)

Publication Number Publication Date
HUE057301T2 true HUE057301T2 (hu) 2022-05-28

Family

ID=57393681

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16800620A HUE057301T2 (hu) 2015-05-22 2016-05-23 Bariátriai eljárást követõ hipoglikémia kezelése GLP-1 antagonistákkal
HUE16800621A HUE055728T2 (hu) 2015-05-22 2016-05-23 Posztbariatrikus hipoglikémia kezelése exendin(9-39)-el

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16800621A HUE055728T2 (hu) 2015-05-22 2016-05-23 Posztbariatrikus hipoglikémia kezelése exendin(9-39)-el

Country Status (17)

Country Link
US (8) US10660937B2 (hu)
EP (4) EP3978011A1 (hu)
AU (4) AU2016267052B2 (hu)
BR (2) BR112017025000A2 (hu)
CA (2) CA3024353A1 (hu)
CL (2) CL2017002913A1 (hu)
CY (2) CY1124616T1 (hu)
DK (2) DK3297653T3 (hu)
ES (2) ES2887723T3 (hu)
HR (2) HRP20211285T1 (hu)
HU (2) HUE057301T2 (hu)
LT (2) LT3297653T (hu)
PL (2) PL3297653T3 (hu)
PT (2) PT3297654T (hu)
RS (2) RS62627B1 (hu)
SI (2) SI3297653T1 (hu)
WO (2) WO2016191394A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2908838T3 (es) 2007-01-08 2022-05-04 Univ Pennsylvania Antagonista del receptor de GLP-1 para usar en el tratamiento del hiperinsulinismo congénito
ES2887723T3 (es) 2015-05-22 2021-12-27 Univ Leland Stanford Junior Tratamiento de hipoglucemia posbariátrica con exendina(9-39)
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP2019535734A (ja) 2016-11-21 2019-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． エキセンディン（９−３９）の緩衝製剤
WO2019147718A1 (en) * 2018-01-23 2019-08-01 Xeris Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
WO2020081534A1 (en) * 2018-10-15 2020-04-23 Eiger Biopharmaceuticals, Inc. Avexitide for the treatment of hyperinsulinemic hypoglycemia
US20220088144A1 (en) * 2019-01-11 2022-03-24 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
WO2024042518A1 (en) * 2022-08-21 2024-02-29 M. Arkin (1999) Ltd Glp-1 receptor antagonist and methods of use thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646128A1 (en) 1992-06-15 1995-04-05 Scios Inc. Glucagon-like peptide and insulinotropin derivatives
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
ES2359031T3 (es) 1996-08-08 2011-05-17 Amylin Pharmaceuticals, Inc. Composición farmacéutica que comprende un péptido de exendina-4.
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
ATE304864T1 (de) 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
CA2305634C (en) 1998-01-30 2006-01-03 Novo Nordisk A/S An injection syringe
AU758968B2 (en) 1998-12-10 2003-04-03 Agouron Pharmaceuticals, Inc. Non-peptide antagonists of GLP-1 receptor and methods of use
DE122007000001I1 (de) 1999-01-14 2007-06-28 Amylin Pharmaceuticals Inc Neue exendin agonist Formulierungen und deren Verabreichung
AU770712B2 (en) 1999-01-14 2004-02-26 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
SE0004462D0 (sv) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
US7638598B2 (en) 2001-04-06 2009-12-29 The Trustees Of The University Of Pennsylvania ErbB interface peptidomimetics and methods of use thereof
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
CN1635900A (zh) 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
JP4532408B2 (ja) 2003-03-13 2010-08-25 田辺三菱製薬株式会社 腫瘍形成抑制剤
MXPA06005581A (es) 2003-11-20 2006-08-11 Novo Nordisk As Formulaciones de peptidos que contienen propilenglicol que son optimas para la produccion y uso en dispositivos de inyeccion.
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
KR101040415B1 (ko) 2004-04-15 2011-06-09 알케르메스,인코포레이티드 중합체 기재 지속적 방출 방법
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
PL1888031T3 (pl) 2005-06-06 2013-04-30 Camurus Ab Preparaty analogu glp-1
SI1971362T1 (sl) 2005-08-19 2015-03-31 Amylin Pharmaceuticals, Llc Eksendin za zdravljenje diabetesa in zmanjšanje telesne mase
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
ES2908838T3 (es) 2007-01-08 2022-05-04 Univ Pennsylvania Antagonista del receptor de GLP-1 para usar en el tratamiento del hiperinsulinismo congénito
DE102007016811A1 (de) 2007-04-05 2008-10-09 Tecpharma Licensing Ag Vorrichtung zur Verabreichung eines fluiden Wirkstoffes aus einer Mehrkammerampulle
EP2144649B1 (de) 2007-04-05 2011-07-20 Tecpharma Licensing AG Verabreichungsvorrichtung mit funktionalem antriebsglied
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
NZ589390A (en) 2008-05-05 2011-11-25 Oramed Ltd Methods and compositions for oral administration of exenatide
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
PT2310042E (pt) 2008-07-08 2013-03-11 Novartis Ag Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena
EP3685837A1 (en) 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
CN102378632A (zh) 2009-04-03 2012-03-14 雀巢产品技术援助有限公司 对促进健康的追赶生长的改进
DK2440228T3 (en) 2009-06-08 2018-12-17 Amunix Operating Inc Glucose regulating polypeptides and methods for their preparation and use
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2768856A4 (en) 2011-10-18 2015-05-27 Prolynx Llc PEG CONJUGATES OF EXENATIDE
WO2013120022A2 (en) 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
ES2887723T3 (es) 2015-05-22 2021-12-27 Univ Leland Stanford Junior Tratamiento de hipoglucemia posbariátrica con exendina(9-39)
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP2019535734A (ja) 2016-11-21 2019-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． エキセンディン（９−３９）の緩衝製剤

Also Published As

Publication number Publication date
EP3297653A4 (en) 2018-12-26
US20210290731A1 (en) 2021-09-23
EP3936143A1 (en) 2022-01-12
US10639354B2 (en) 2020-05-05
AU2016267052B2 (en) 2022-01-20
WO2016191394A1 (en) 2016-12-01
BR112017024997A2 (pt) 2018-07-31
CY1124616T1 (el) 2022-07-22
ES2897955T3 (es) 2022-03-03
US10993991B2 (en) 2021-05-04
EP3297654A1 (en) 2018-03-28
WO2016191395A1 (en) 2016-12-01
EP3297654B1 (en) 2021-07-07
CA3024358A1 (en) 2016-12-01
US20200276271A1 (en) 2020-09-03
ES2887723T3 (es) 2021-12-27
US20240000894A1 (en) 2024-01-04
US11622995B2 (en) 2023-04-11
SI3297653T1 (sl) 2022-01-31
US11617782B2 (en) 2023-04-04
AU2016267052A1 (en) 2017-12-14
US20200276272A1 (en) 2020-09-03
EP3297653A1 (en) 2018-03-28
CY1125147T1 (el) 2023-03-24
RS62368B1 (sr) 2021-10-29
DK3297654T3 (da) 2021-09-06
CA3024353A1 (en) 2016-12-01
US10993992B2 (en) 2021-05-04
HRP20211768T1 (hr) 2022-02-18
AU2016267057A1 (en) 2017-12-14
LT3297654T (lt) 2021-10-25
AU2022202506A1 (en) 2022-05-12
BR112017025000A2 (pt) 2018-08-07
AU2016267057B2 (en) 2021-12-23
EP3297653B1 (en) 2021-09-15
US20230346890A1 (en) 2023-11-02
EP3978011A1 (en) 2022-04-06
HRP20211285T1 (hr) 2022-01-07
RS62627B1 (sr) 2021-12-31
PT3297653T (pt) 2021-10-25
EP3297654A4 (en) 2018-04-11
LT3297653T (lt) 2022-01-10
PL3297653T3 (pl) 2022-01-31
PL3297654T3 (pl) 2021-12-20
US12102663B2 (en) 2024-10-01
AU2022201973A1 (en) 2022-04-14
SI3297654T1 (sl) 2021-11-30
HUE055728T2 (hu) 2021-12-28
US20210315974A1 (en) 2021-10-14
DK3297653T3 (da) 2021-10-18
US20180147261A1 (en) 2018-05-31
CL2017002911A1 (es) 2018-05-25
PT3297654T (pt) 2021-09-06
US10660937B2 (en) 2020-05-26
US20180117122A1 (en) 2018-05-03
CL2017002913A1 (es) 2018-06-01

Similar Documents

Publication Publication Date Title
IL251741A0 (en) Co-agonists for glucagon and 1- glp receptors
SI3368101T1 (sl) Avtoinjektor za enkratno uporabo
ZA201802017B (en) Novel insulin analogs and use thereof
PL3297653T3 (pl) Leczenie hipoglikemii po operacji bariatrycznej antagonistami GLP-1
HK1248552A1 (zh) 使用川地匹坦的治療方法
HK1244722A1 (zh) 可伸縮針式注射器
AU362192S (en) Bath
TWD174558S (zh) 浴缸之部分
IL251013A0 (en) Implantable electrode
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
HK1250329A1 (zh) 使用祖細胞治療眼部病症
PT3188778T (pt) Injetor tipo caneta
PL3139948T3 (pl) Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
GB201412010D0 (en) Treatment of hypertransaminasemia
PT3139948T (pt) Tratamento de diabetes usando glp-1 e anti-il-21
GB201513922D0 (en) Treatment of hyperpigmentation
GB201417423D0 (en) Bath
GB201400235D0 (en) Treatment
GB201400238D0 (en) Treatment